152 related articles for article (PubMed ID: 9180388)
1. The effect of ethyldeshydroxy-sparsomycin and cisplatin on the intracellular glutathione level and glutathione S-transferase activity.
Hofs HP; Wagener TD; de Valk-Bakker V; van Rennes H; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1997 Apr; 8(4):349-57. PubMed ID: 9180388
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; Van Zeist AJ; Van Den Broek LA; Ottenheijm HC
Anticancer Res; 1992; 12(1):167-70. PubMed ID: 1567164
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; van Zeist AJ; van den Broek LA; Ottenheijm HC
Cancer Chemother Pharmacol; 1993; 31(4):289-94. PubMed ID: 8422692
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent enhancement of antitumor activity of ethyldeshydroxy-sparsomycin in combination with classical antineoplastic agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; de Vos D; Doesburg WH; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1995 Apr; 6(2):277-84. PubMed ID: 7795276
[TBL] [Abstract][Full Text] [Related]
5. Antitumour activity and retinotoxicity of ethyldeshydroxy-sparsomycin in mice.
Hofs HP; Wagener DJ; De Vos D; Ottenheijm HC; Winkens HJ; Bovee PH; De Grip WJ
Eur J Cancer; 1995; 31A(9):1526-30. PubMed ID: 7577083
[TBL] [Abstract][Full Text] [Related]
6. Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.
Hofs HP; Wagener DJ; De Valk-Bakker V; Van Rennes H; De Vos D; Doesburg WH; Ottenheijm HC; De Grip WJ
Invest New Drugs; 1995; 13(1):23-32. PubMed ID: 7499104
[TBL] [Abstract][Full Text] [Related]
7. Concentration and sequence dependent synergism of ethyldeshydroxy-sparsomycin in combination with antitumor agents.
Hofs HP; Wagener DJ; de Valk-Bakker V; van Rennes H; Ottenheijm HC; de Grip WJ
Anticancer Drugs; 1994 Feb; 5(1):35-42. PubMed ID: 8186428
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of cisplatin antitumor activity on L1210 leukemia s.c. by sparsomycin and three of its analogues.
Zylicz Z; Hofs HP; Wagener DJ
Cancer Lett; 1989 Jul; 46(2):153-7. PubMed ID: 2752385
[TBL] [Abstract][Full Text] [Related]
9. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
[TBL] [Abstract][Full Text] [Related]
10. Effects of flavonoids on glutathione and glutathione-related enzymes in cisplatin-treated L1210 leukemia cells.
Cipák L; Berczeliová E; Paulíková H
Neoplasma; 2003; 50(6):443-6. PubMed ID: 14689067
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
12. Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo.
Ribrag V; Massaad L; Janot F; Bissery MC; Parise O; Gouyette A; Chabot GG
Leuk Res; 1994 Nov; 18(11):829-35. PubMed ID: 7967709
[TBL] [Abstract][Full Text] [Related]
13. The role of platinum uptake and glutathione levels in L1210 cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Nicolson MC; Orr RM; O'Neill CF; Harrap KR
Neoplasma; 1992; 39(3):189-95. PubMed ID: 1528325
[TBL] [Abstract][Full Text] [Related]
14. Severe depletion of cellular thiols and glutathione-related enzymes of a carmustine-resistant L1210 strain associates with collateral sensitivity to cyclophosphamide.
Institoris E; Tretter L; Gaál D
Cancer Chemother Pharmacol; 1993; 33(1):85-8. PubMed ID: 8269595
[TBL] [Abstract][Full Text] [Related]
15. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
Peters RH; Jollow DJ; Stuart RK
Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity, cellular uptake and DNA binding of the novel trinuclear platinun complex BBR 3464 in sensitive and cisplatin resistant murine leukemia cells.
Di Blasi P; Bernareggi A; Beggiolin G; Piazzoni L; Menta E; Formento ML
Anticancer Res; 1998; 18(4C):3113-7. PubMed ID: 9713519
[TBL] [Abstract][Full Text] [Related]
17. Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity.
Dwivedi C; Abu-Ghazaleh A; Guenther J
Anticancer Drugs; 1996 Sep; 7(7):792-4. PubMed ID: 8949992
[TBL] [Abstract][Full Text] [Related]
18. The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents.
Hrubisko M; McGown AT; Fox BW
Biochem Pharmacol; 1993 Jan; 45(1):253-6. PubMed ID: 8424817
[TBL] [Abstract][Full Text] [Related]
19. Modulation of thiol pools by vitamin K3 and its effect on survival of sensitive and resistant murine tumor cells.
Parekh H; Chavan S; Chitnis M
Anticancer Drugs; 1991 Apr; 2(2):159-68. PubMed ID: 1683589
[TBL] [Abstract][Full Text] [Related]
20. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
Ali-Osman F; Stein DE; Renwick A
Cancer Res; 1990 Nov; 50(21):6976-80. PubMed ID: 2208164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
